文献速递淋巴瘤

不同组织学分级滤泡性淋巴瘤的分子图谱:基因组与转录组分析的见解

Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.
PubMed 文献 · Leukemia · 2025-04-15

本研究分析831例患者临床数据、149例全外显子组测序和63例转录组测序,探索FL1-2、FL3A、FL3B与FL/DLBCL差异。临床分惰性组(FL1-2和FL3A)与侵袭性组(FL3B和FL/DLBCL);FL1-2与FL3A遗传背景相似,FL3B与FL/DLBCL缺乏CREBBP和KMT2D突变但具额外拷贝数变异;转录组显示随分级升高免疫通路活性降低而代谢和细胞周期通路活性增加。

要点

  • 临床分析显示FL1-2和FL3A为惰性组,FL3B和FL/DLBCL为侵袭性组。
  • FL1-2与FL3A共享遗传背景,FL3B和FL/DLBCL缺乏CREBBP和KMT2D突变。
  • FL3B和FL/DLBCL具有1p36.32缺失和3p21.1获得等额外拷贝数变异。

核心结论

  • FL3B和FL/DLBCL在生物学和临床上为不同于传统FL的B细胞淋巴瘤。
  • FL1-2和FL3A的差异在于肿瘤微环境而非遗传图谱。

研究设计与样本

  • 分析831例患者临床数据、149例患者全外显子组测序和63例患者转录组测序。
  • 比较FL1-2、FL3A、FL3B和FL/DLBCL亚组。

主要发现

  • 临床分析显示惰性组(FL1-2和FL3A)预后良好,侵袭性组(FL3B和FL/DLBCL)预后差。
  • 基因组学显示FL1-2和FL3A共享共同遗传背景。
  • FL3B和FL/DLBCL缺乏表观遗传调控因子CREBBP和KMT2D突变,但 exhibit 额外拷贝数变异如1p36.32缺失和3p21.1获得,与不良预后相关。
  • 转录组学显示随组织学分级升高,免疫相关通路活性降低,代谢和细胞周期通路活性增加,可能与MYC、IRF4和BATF表达上调相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2022 World Health Organization Classification of Haematolymphoid tumours classifies follicular lymphoma grades 1-2 (FL1-2) and grade 3A (FL3A) as classic follicular lymphoma (cFL) and reclassifies grade 3B (FL3B) as follicular large B-cell lymphoma (FLBL), without addressing cases of patients with concurrent FL and diffuse large B-cell lymphoma (FL/DLBCL). However, genetic information on FL histologic grading remains limited, and the latest classification lacks sufficient evidence to resolve whether these subgroups represent single or multiple distinct biological entities. This study analyzed clinical data from 831 patients, whole-exome sequencing (WES) from 149 patients, and transcriptome sequencing from 63 patients to explore differences among FL1-2, FL3A, FL3B, and FL/DLBCL. Clinical analyses revealed two distinct groups: an indolent group (FL1-2 and FL3A) with favorable prognosis and an aggressive group (FL3B and FL/DLBCL) characterized by poor prognosis. Genomics revealed that FL1-2 and FL3A share a common genetic background, whereas FL3B and FL/DLBCL lack mutations in epigenetic regulators CREBBP and KMT2D but exhibit additional copy number variations (CNVs), such as 1p36.32 losses and 3p21.1 gains, which are linked to poor prognosis. Transcriptomics revealed that with increasing histologic grade, immune-related pathway activity decreases, while the activity of metabolic and cell cycle pathways increases, which may be associated with the upregulation of MYC, IRF4, and BATF expression. Together, these findings define FL3B and FL/DLBCL as biologically and clinically distinct B-cell lymphomas, differing from traditional FL. FL1-2 and FL3A differ in their tumor microenvironments rather than genetic profiles.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sun C, Li W, Yu J, et al. Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses. Leukemia. 2025. PMID: 40234612. doi:10.1038/s41375-025-02603-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。